Optimizerx CORP

OptimizeRx shareholders approved an increase of 1,000,000 shares to the 2021 Equity Incentive Plan at the 2026 Annual Meeting.

OptimizeRx Corporation announced the departure of Chief Commercial Officer Theresa Greco, effective June 15, 2026, under a separation and advisory agreement.

OptimizeRx Corporation announced a new $35 million senior secured credit facility and updated its fiscal year 2026 financial outlook, projecting revenues between $95-$100 million and maintaining adjusted EBITDA guidance.

OptimizeRx dismissed UHY and appointed Grant Thornton as its independent auditor, reporting no disagreements and reiterating a previously disclosed internal control material weakness.

OptimizeRx announced strong fourth quarter and full year 2025 financial results, including record net income and adjusted EBITDA, alongside updated 2026 guidance and a new $10 million share repurchase program.

OptimizeRx Corporation announced robust third-quarter 2025 financial results, including a 22% revenue increase and a significant jump in net income, leading to an upward revision of its full-year 2025 guidance and introduction of 2026 projections.

OptimizeRx Corporation reported a significant financial turnaround, achieving net income for the quarter and nine-month period ended September 30, 2025, driven by robust revenue growth and improved margins.

OptimizeRx Corporation reported a significant financial turnaround in Q2 2025, achieving net income and strong revenue growth driven by DTC and DAAP sales.

OptimizeRx's Q1 2025 revenue increased by 11% year-over-year, driven by growth in DTC and DAAP related sales, while net loss decreased significantly.

OptimizeRx Corporation saw a 30% increase in revenue in the third quarter of 2024 compared to the same period last year, driven by the acquisition of Medicx Health and growth in DAAP related sales, but still reported a net loss.

OptimizeRx Corporation saw a significant increase in revenue for the second quarter of 2024, primarily due to the acquisition of Medicx Health and growth in its DAAP program.

OptimizeRx Corporation saw a 51% increase in net revenue in the first quarter of 2024, primarily due to the acquisition of Medicx Health and growth in its DAAP solutions.

OptimizeRx's 2024 10-K filing reveals a revenue increase driven by acquisitions and DAAP sales, but also highlights a net loss and ongoing efforts to improve financial controls.

OptimizeRx's 2023 annual report highlights a 15% revenue increase to $71.5 million, fueled by strategic acquisitions and the expansion of its AI-powered platform.

OptimizeRx Corp. reports that Director Cathy Klema acquired 34,517 shares of common stock on June 9, 2026, through a grant of restricted stock units.

OptimizeRx Corp director James Paul Lang acquired 34,517 shares of common stock through a restricted stock unit grant.

OptimizeRx Corp. reports a Form 4 filing detailing a director's acquisition of restricted stock units.

OptimizeRx Corp. reports a grant of restricted stock units to Director Patrick D. Spangler, vesting in one year or at the next annual meeting.

OptimizeRx Corp. reports a grant of restricted stock units to Director Ellen O'Connor Vos.

OptimizeRx Corp. reports that Director Gregory D. Wasson was granted restricted stock units (RSUs) on June 9, 2026, vesting on the earlier of the first anniversary of the grant or the company's next annual meeting.

OptimizeRx Corporation has issued its proxy statement detailing the agenda for its upcoming Annual Meeting of Shareholders on June 9, 2026, including proposals to amend its 2021 Equity Incentive Plan.

OptimizeRx Corporation will hold its annual stockholders meeting virtually on June 11, 2025, to vote on director elections, executive compensation, and auditor ratification.

OptimizeRx has received notice from Whetstone Capital Advisors regarding their intention to nominate two candidates for election to the Board of Directors at the upcoming 2025 Annual Meeting.

OptimizeRx Corporation is holding its annual virtual meeting on June 5, 2024, to vote on director elections, executive compensation, an equity incentive plan amendment, and auditor ratification.

Whetstone Capital Advisors, a significant shareholder in OptimizeRx Corporation, has conditionally withdrawn its nominations for the company's 2025 annual meeting board election, following an agreement with OptimizeRx to appoint a new independent director.

Whetstone Capital Advisors, holding an 8.2% stake in OptimizeRx Corporation, has formally nominated Andrew Carlson and John Fein for election to the company's Board of Directors at the upcoming 2025 annual meeting.

Whetstone Capital Advisors and David Atterbury have disclosed an 8.2% stake in OptimizeRx Corporation, urging the company's Board of Directors to consider strategic alternatives, including a full sale, to maximize shareholder value.

Royce & Associates LP has disclosed beneficial ownership of 1,089,398 shares, representing 5.81% of the outstanding common stock of OptimizeRx Corp.

The Vanguard Group has reported a 0% beneficial ownership in OptimizeRx Corp common stock following an internal realignment.

The Vanguard Group has reported a 5.7% beneficial ownership stake in OptimizeRx Corp, holding over 1 million shares as of September 30, 2025.

Royce & Associates LP, an investment adviser, has filed an amended Schedule 13G disclosing a 4.27% beneficial ownership stake in OptimizeRx Corp.

The Vanguard Group has filed an Amendment No. 3 to its Schedule 13G, disclosing a 4.98% passive beneficial ownership in OptimizeRx Corp's Common Stock as of March 31, 2025.

An amended Schedule 13G filing reveals that Samjo Management, LLC and Andrew N. Wiener beneficially own a combined 50 shares, representing 0.0% of OptimizeRx Corporation's common stock, indicating a passive and non-influential holding.